Xenon Pharmaceuticals (XENE) Long-Term Deferred Tax (2018 - 2026)

Xenon Pharmaceuticals (XENE) has 9 years of Long-Term Deferred Tax data on file, last reported at $12.4 million in Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 14.14% year-over-year to $12.4 million in Q1 2026; TTM through Mar 2026 was $12.4 million, a 14.14% increase from a year earlier, with the FY2025 full-year figure at $12.9 million, up 33.09% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $12.4 million, down from $12.9 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for XENE reached as high as $12.9 million in Q4 2025 and fell as low as $207000.0 in Q1 2022.
• Historically, Long-Term Deferred Tax has averaged $4.4 million across 5 years, with a median of $733000.0 in 2024.
• Across the five-year window, Long-Term Deferred Tax plunged 99.05% in 2022 and soared 2619.75% in 2025, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $509000.0 in 2022, then soared by 57.56% to $802000.0 in 2023, then surged by 1105.24% to $9.7 million in 2024, then soared by 33.09% to $12.9 million in 2025, then slipped by 3.47% to $12.4 million in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $12.4 million in Q1 2026, $12.9 million in Q4 2025, and $11.8 million in Q3 2025.